Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability

• Published in: Epilepsia (Copenhagen) 2007-07, Vol.48 (7), p.1351-1359
• Main Authors: Hirsch, Lawrence J., Arif, Hiba, Buchsbaum, Richard, Weintraub, David, Lee, Jeansun, Chang, Jennifer T., Resor, Stanley R., Bazil, Carl W.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anticonvulsants - adverse effects; Anticonvulsants - pharmacokinetics; Anticonvulsants - therapeutic use; Anticonvulsants. Antiepileptics. Antiparkinson agents; Biological and medical sciences; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Induction - drug effects; Epilepsy - blood; Epilepsy - diagnosis; Epilepsy - drug therapy; Female; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Male; Medical sciences; Metabolic Clearance Rate - drug effects; Metabolic Clearance Rate - physiology; Middle Aged; Nervous system (semeiology, syndromes); Neurology; Neuropharmacology; Neuroprotective agent; Pharmacology. Drug treatments; Piracetam - adverse effects; Piracetam - analogs & derivatives; Piracetam - pharmacokinetics; Piracetam - therapeutic use; Retrospective Studies
• ISSN: 0013-9580; 1528-1167
• DOI: 10.1111/j.1528-1167.2007.01043.x

Purpose: To compare pharmacokinetics and tolerability of levetiracetam (LEV) in older versus younger adults. Methods: As part of the Columbia Antiepileptic Drug Database, we retrospectively studied the pharmacokinetics and tolerability of LEV in patients who had been seen as an outpatient at our center during a 4‐year period. We compared apparent clearance (CL) of LEV in the youngest (16–31 years; n = 151) and oldest (55–88 years; n = 157) quartile of 629 adult outpatients who had taken LEV. We also analyzed the frequency of adverse effects leading to dose change or discontinuation (“intolerability”) and specific adverse effects in the younger versus older adults. One‐year retention was determined for younger and older adults newly started on LEV at our center. Results: Mean LEV CL differed significantly between older (46.5 ml/h/kg) and younger adults (78.3 ml/h/kg). On average, older patients had a 40% lower LEV CL than younger patients. Comedication with an enzyme‐inducing antiepileptic drug (EIAED; mostly carbamazepine) was associated with a 24% higher clearance of LEV compared to those who were not on EIAEDs. This difference was 37% in a subgroup of patients whose LEV CL was compared while they were on and off EIAEDs. Stepwise linear regression identified younger age and comedication with an EIAED as significant predictors of increased LEV CL. A total of 34.3% of the 629 patients (31.7% of younger vs. 40.7% of older patients; p = 0.16) reported intolerability to LEV on at least one occasion. This difference in tolerability reached significance in the group of patients newly started on LEV (26.3% vs. 41.0%; p = 0.017). Drowsiness and psychiatric/behavioral side effects were the most common adverse effects associated with LEV use in both age groups. One‐year retention was 72% in the older group vs. 54% in the younger group (not significant). Conclusion: Older adults have lower CL than younger adults and require a mean 40% lower dose of LEV to achieve the same serum level. Comedication with an EIAED increases LEV CL by 24–37%. Younger adults tolerate LEV better than older adults, but 1‐year retention was (nonsignificantly) higher in the older group.